So what does that journey actually look like
Occupancy stays low, but each engaged receptor keeps sending its main message longer than it would under a balanced signal (cAMP bias with low receptor internalization). In a head-to-head trial against liraglutide, tirzepatide reduced measured food intake and craving more despite lower GLP-1 occupancy. The effect lowers the drive to eat rather than increasing restraint
This means that there is zero regulation, proven usage recommendations, quality assurance or safety testing
A patient with gut symptoms may need evaluation for inflammatory bowel disease, infection, celiac disease, medication effects, food reactions, or other causes
Something to bear in mind
Email and chat responses came within 24 hours, and I felt like my questions were actually being addressed